Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Mannheim/Ontogeny $40 mil. R&D agreement focuses on bone disorder research.

Executive Summary

BOEHRINGER MANNHEIM/ONTOGENY $40 MIL. BONE DISORDER R&D AGREEMENT will involve application of Cambridge, Mass.-based Ontogeny's "hedgehog" molecule research to treatment of bone, cartilage and other skeletal disorders. Ontogeny will receive milestone payments, and Boehringer Mannheim will acquire a less than 5% equity stake in Ontogeny as part of the five-year program.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029024

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel